grey arrow to go to previous Omnicell webpage or forward to next Omnicell pageBack to Press Release

October 22, 2009

Omnicell Announces Third Quarter 2009 Results

Download PDF

MOUNTAIN VIEW, Calif., Oct 22, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Omnicell, Inc. (Nasdaq: OMCL), a leading provider of system solutions to acute healthcare facilities, today announced results for its third quarter ended September 30, 2009.

GAAP results: Revenue for the third quarter of 2009 was $54.0 million, up $1.3 million or 2.5% from the second quarter of 2009, and down $10.4 million or 16.1% from the third quarter of 2008.

Third quarter 2009 net income as reported in accordance with U.S. generally accepted accounting principles (GAAP) was $0.9 million, or $0.03 per diluted share. This compares to net income of $0.9 million, or $0.03 per diluted share in the second quarter of 2009 and net income of $2.9 million, or $0.09 per diluted share in the third quarter of 2008.

Non-GAAP results: Excluding the impact on our results of recording $2.4 million in stock-based compensation expense related to ASC 718, "Stock Compensation" (formerly referred to as SFAS No. 123R), non-GAAP net income was $3.3 million for the third quarter of 2009, or $0.10 per diluted share. This compares to non-GAAP net income of $3.3 million, or $0.10 per diluted share for the second quarter of 2009, which excludes $2.4 million in stock compensation expense. Third quarter 2009 results compare to non-GAAP net income of $5.7 million, or $0.18 per diluted share for the third quarter of 2008.

"I am pleased with our performance in the third quarter," said Randall Lipps, Omnicell President, Chairman and CEO. "The marketplace has reacted favorably to our steady expansion of patient safety and workflow management solutions. In the third quarter we began shipping our latest major software release, Omnicell 14.0, which gives our customers enhanced operating room anesthesia solutions and introduces our new proprietary Anywhere RN technology, which allows Omnicell cabinet transactions to be managed by nurses from virtually any workstation in the hospital, saving time and increasing efficiency in medication management. In addition, we are in the midst of going live at several large hospitals in both the domestic and international markets. Our solutions continue to attract new and existing customers who are committed to having the safest and most effective automation capabilities in their facilities, such as Barnes-Jewish Hospital--a U.S. News & World Report Top Hospital and Missouri's largest--to implement the Omnicell OptiFlex point-of-use supply solution in their operating rooms and cath labs."

Omnicell Conference Call Information

Omnicell will hold a conference call today at 1:30 p.m. PDT to discuss third quarter financial results. The conference call can be monitored by dialing 1-800-696-5518 within the U.S. or 1-706-758-4883 for all other locations. The Conference ID # is 20153924. Internet users can access the conference call at A replay of the call will be available today at approximately 2:30 p.m. PDT and will be available until 8:59 p.m. PDT on October 30. The replay access numbers are 1-800-642-1687 within the U.S. and 1-706-645-9291 for all other locations, conference code # 20153924.

About Omnicell

Omnicell, Inc. (NASDAQ: OMCL) is a leading provider of systems and software solutions targeting patient safety and operational efficiency in healthcare facilities. Since 1992, Omnicell has worked to enhance patient safety and allow clinicians to spend more time with their patients.

Omnicell medication-use product lines include solutions for the central pharmacy, nursing unit, operating room, and patient bedside. Solutions range from large central pharmacy "smart inventory" carousels to small handheld devices. From the point at which a medication arrives at the receiving dock to the time it is administered, Omnicell systems store it, package it, bar code it, order it, issue it, and provide information and controls on its use and reorder.

Omnicell supply product lines provide a healthcare institution with fast, effective control of costs, capture of charges for payer reimbursement, and timely reorder of supplies. Products range from high-security closed-cabinet systems and software to open-shelf and combination solutions in the nursing unit, cath lab and operating room.

Omnicell's mission is to provide the best customer experience in healthcare, helping hospitals reduce medication errors, operate more efficiently, and decrease costs. For more information, visit

Forward-Looking Statements

To the extent any statements contained in this release deal with information that is not historical, these statements are necessarily forward-looking. As such, they are subject to the occurrence of many events outside Omnicell's control and are subject to various risk factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statement. The risk factors are described in the Company's Securities and Exchange Commission (SEC) filings and include, without limitation, the unfavorable general economic and market conditions, the tightening in the credit market, the continued growth and acceptance of our products and services and the continued growth of the clinical automation and workflow automation market generally, the potential of increasing competition, the ability of the company to grow product backlog, retain key personnel, cut expenses, manage future changes in revenue levels, develop new products and integrate acquired products or intellectual property in a timely and cost-effective manner, and improve sales productivity. Prospective investors are cautioned not to place undue reliance on forward-looking statements.

Use of Non-GAAP Financial Information

This press release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles (GAAP). Our management evaluates and makes operating decisions using various performance measures. In addition to Omnicell's GAAP results, we also consider non-GAAP gross profit, non-GAAP operating expenses, non-GAAP net income, and non-GAAP earnings per diluted share. These non-GAAP results should not be considered as an alternative to gross profit, operating expenses, net income, earnings per diluted share, or any other performance measure derived in accordance with GAAP. We present these non-GAAP results because we consider them to be important supplemental measures of Omnicell's performance.

Our non-GAAP gross profit, non-GAAP operating expenses, non-GAAP net income, and non-GAAP earnings per diluted share are exclusive of certain items to facilitate management's review of the comparability of Omnicell's core operating results on a period to period basis because such items are not related to Omnicell's ongoing core operating results as viewed by management. We define our "core operating results" as those revenues recorded in a particular period and the expenses incurred within that period that directly drive operating income in that period. Management uses these non-GAAP financial measures in making operating decisions because, in addition to meaningful supplemental information regarding operating performance, the measures give us a better understanding of how we should invest in research and development, fund infrastructure growth and evaluate the effectiveness of marketing strategies. In calculating the above non-GAAP results, management specifically adjusted for the following excluded items:

a) Stock-based compensation expense impact of ASC 718. We recognize equity plan-related compensation expenses, which represents the fair value of all stock-based payments to employees, including grants of employee stock options, as required under ASC 718, "Stock Compensation".

b) Restructuring charges (net of tax). We incurred charges for employee severance in connection with a reduction in force in the first quarter of 2009, which was designed to align our cost structure with current business expectations. These charges are not expected to be recurring and, as a non-recurring event, the financial impact is excluded from our non-GAAP results.

Management adjusts for the above items because management believes that, in general, these items possess one or more of the following characteristics: their magnitude and timing is largely outside of Omnicell's control; they are unrelated to the ongoing operation of the business in the ordinary course; they are unusual and we do not expect them to occur in the ordinary course of business; or they are non-operational, or non-cash expenses involving stock option grants.

We believe that the presentation of these non-GAAP financial measures is warranted for several reasons:

1) Such non-GAAP financial measures provide an additional analytical tool for understanding Omnicell's financial performance by excluding the impact of items which may obscure trends in the core operating results of the business;

2) Since we have historically reported non-GAAP results to the investment community, we believe the inclusion of non-GAAP numbers provides consistency and enhances investors' ability to compare our performance across financial reporting periods;

3) These non-GAAP financial measures are employed by Omnicell's management in its own evaluation of performance and are utilized in financial and operational decision making processes, such as budget planning and forecasting; and

4) These non-GAAP financial measures facilitate comparisons to the operating results of other companies in our industry, which use similar financial measures to supplement their GAAP results, thus enhancing the perspective of investors who wish to utilize such comparisons in their analysis of our performance.

Set forth below are additional reasons why stock-based compensation expense related to ASC 718 is excluded from our non-GAAP financial measures:

i) While stock-based compensation calculated in accordance with ASC 718 constitutes an ongoing and recurring expense of Omnicell, it is not an expense that requires cash settlement by Omnicell. We therefore exclude these charges for purposes of evaluating core operating results. Thus, our non-GAAP measurements are presented exclusive of stock-based compensation expense to assist management and investors in evaluating our core operating results.

ii) We present ASC 718 stock-based payment compensation expense in our reconciliation of non-GAAP financial measures on a pre-tax basis because the exact tax differences related to the timing and deductibility of stock-based compensation, under ASC 718, are dependent upon the trading price of Omnicell's common stock and the timing and exercise by employees of their stock options. As a result of these timing and market uncertainties the tax effect related to stock-based compensation expense would be inconsistent in amount and frequency and is therefore excluded from our non-GAAP results.

As stated above, we present non-GAAP financial measures because we consider them to be important supplemental measures of performance. However, non-GAAP financial measures have limitations as an analytical tool and should not be considered in isolation or as a substitute for Omnicell's GAAP results. In the future, we expect to incur expenses similar to certain of the non-GAAP adjustments described above and expect to continue reporting non-GAAP financial measures excluding such items. Some of the limitations in relying on non-GAAP financial measures are:

    --  Omnicell's stock option and stock purchase plans are important
        components of incentive compensation arrangements and will be reflected
        as expenses in Omnicell's GAAP results for the foreseeable future under
        ASC 718.

    --  Other companies, including other companies in Omnicell's industry, may
        calculate non-GAAP financial measures differently than Omnicell,
        limiting their usefulness as a comparative measure.

Pursuant to the requirements of SEC Regulation G, a detailed reconciliation between Omnicell's non-GAAP and GAAP financial results is set forth in the financial tables at the end of this press release. Investors are advised to carefully review and consider this information strictly as a supplement to the GAAP results that are contained in this press release and in Omnicell's SEC filings.


                                     Omnicell, Inc.
                     Condensed Consolidated Statements of Operations
                    (in thousands, except per share data, unaudited)

                         Three Months Ended          Nine Months Ended
              September        June         September   September   September
                 30,            30,            30,         30,         30,
                2009           2009           2008        2009        2008
     Product   $42,854        $41,983        $54,294      $127,221  $159,580
      revenues  11,103         10,660         10,051        31,583    30,230
     revenue    53,957         52,643         64,345       158,804   189,810

    Cost of
     Cost of
      revenues  20,087         19,175         24,940        59,542    73,259
     Cost of
      and other
      revenues   6,621          6,539          6,642        20,055    19,083
     charges         --              --              --         1,209         -
    Total cost
     revenues   26,708         25,714         31,582        80,806    92,342

     profit     27,249         26,929         32,763        77,998    97,468
      ment       4,981          4,574          4,685        13,532    13,939
      rative    21,324         21,038         23,862       63,861     69,947
      charges        --              --              --        1,315          --
     expenses   26,305         25,612         28,547       78,708     83,886
     operations    944          1,317          4,216         (710)    13,582
      net           56            194            673          433      2,804
      taxes       1,000         1,511          4,889         (277)    16,386
     taxes          146           607          1,975         (165)     6,985
     (loss)        $854          $904         $2,914        $(112)    $9,401

     Basic        $0.03         $0.03          $0.09           $--      $0.29
     Diluted      $0.03         $0.03          $0.09           $--      $0.28

     Basic       31,704        31,578         31,128       31,578     32,345
     Diluted     32,380        31,961         32,138       31,578     33,498

                               Omnicell, Inc.
                   Condensed Consolidated Balance Sheets
                               (In thousands)

                                      September 30,      December 31,
                                         2009               2008
                                      (unaudited)           (1)
    Current assets:
      Cash and cash equivalents         $146,312          $120,439
      Accounts receivable, net            58,779            57,976
      Inventories                         10,445            12,957
      Prepaid expenses                     9,451             9,310
      Deferred tax assets                 14,871            14,871
      Other current assets                 6,083             9,434
        Total current assets             245,941           224,987

    Property and equipment, net           13,128            16,180
    Non-current net investment
     in sales-type leases                  9,470            10,896
    Goodwill                              24,982            24,982
    Other intangible assets                4,847             6,706
    Non-current deferred tax assets       15,730            15,889
    Other assets                           8,938             8,902
          Total assets                  $323,036          $308,542

    Current liabilities:
      Accounts payable                   $10,430            $9,377
      Accrued compensation                 7,621             8,889
      Accrued liabilities                 11,585            10,357
      Deferred service revenue            14,359            12,084
      Deferred gross profit               16,649            16,648
        Total current liabilities         60,644            57,355

    Long-term deferred service revenue    17,181            16,782
    Other long-term liabilities              752               848
        Total liabilities                 78,577            74,985

    Stockholders' equity:
        Total stockholders' equity       244,459           233,557
          Total liabilities and
           stockholders' equity         $323,036          $308,542

    (1) Information derived from our December 31, 2008 audited Consolidated
        Financial Statements.

                                Omnicell, Inc.
                       Reconciliation of GAAP to Non-GAAP
                (In thousands, except per share data, unaudited)

                                   Three months ended
                 September 30, 2009  June 30, 2009  September 30, 2008

                            Earnings        Earnings          Earnings
                              per             per               per
                   Net      share-    Net   share-    Net      share-
                  income    diluted  income diluted  income    diluted

    GAAP           $854      $0.03    $904   $0.03   $2,914     $0.09
    ASC 718
     Adjustment (a)
       Margin       360                287              400
       Expenses   2,053              2,087            2,368
                  2,413       0.07   2,374    0.07    2,768      0.09

    Non-GAAP     $3,267      $0.10  $3,278   $0.10   $5,682     $0.18

                             Nine months ended
                 September 30, 2009  September 30, 2008

                   Net     (loss) per        Earnings
                  Income    share -   Net   per share-
                  (loss)    diluted  income  diluted

    GAAP          $(112)        $--  $9,401   $0.28
    ASC 718
     adjustment (a)
       Margin     1,025              1,326
       Expenses   6,246              7,442
     cost (net of
     tax) (b)
       profit       735
       expenses     799
                  8,805       0.28   8,768    0.26
    Non-GAAP     $8,693      $0.28 $18,169   $0.54

    (a) This adjustment reflects the accounting impact of non-cash stock-
        based compensation expense related to the impact of ASC 718 (formerly
        referred to as SFAS No. 123R) for the periods shown.

    (b) This is the net of tax impact of the restructuring activities
        executed during the first quarter of 2009.

SOURCE Omnicell, Inc.

Copyright (C) 2009 PR Newswire. All rights reserved